These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 38761584)

  • 21. Spiro-oxindoles as a Promising Class of Small Molecule Inhibitors of p53-MDM2 Interaction Useful in Targeted Cancer Therapy.
    Gupta AK; Bharadwaj M; Kumar A; Mehrotra R
    Top Curr Chem (Cham); 2017 Feb; 375(1):3. PubMed ID: 27943171
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011-present).
    Zak K; Pecak A; Rys B; Wladyka B; Dömling A; Weber L; Holak TA; Dubin G
    Expert Opin Ther Pat; 2013 Apr; 23(4):425-48. PubMed ID: 23374098
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
    Hu B; Gilkes DM; Chen J
    Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Simple Structural Modifications Converting a Bona fide MDM2 PROTAC Degrader into a Molecular Glue Molecule: A Cautionary Tale in the Design of PROTAC Degraders.
    Yang J; Li Y; Aguilar A; Liu Z; Yang CY; Wang S
    J Med Chem; 2019 Nov; 62(21):9471-9487. PubMed ID: 31560543
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Small-molecule inhibitors of the p53-MDM2 interaction.
    Vu BT; Vassilev L
    Curr Top Microbiol Immunol; 2011; 348():151-72. PubMed ID: 21046355
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MDM2-PROTAC versus MDM2 Inhibitors: Beyond p53 Reactivation.
    Peuget S; Selivanova G
    Cancer Discov; 2023 May; 13(5):1043-1045. PubMed ID: 37139722
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Small-molecule inhibitors of MDM2 as new anticancer therapeutics.
    Dickens MP; Fitzgerald R; Fischer PM
    Semin Cancer Biol; 2010 Feb; 20(1):10-8. PubMed ID: 19897042
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficient reactivation of p53 in cancer cells by a dual MdmX/Mdm2 inhibitor.
    Qin L; Yang F; Zhou C; Chen Y; Zhang H; Su Z
    J Am Chem Soc; 2014 Dec; 136(52):18023-33. PubMed ID: 25453499
    [TBL] [Abstract][Full Text] [Related]  

  • 29. p53-Mdm2 inhibitors: patent review (2009 - 2010).
    Kamal A; Mohammed AA; Shaik TB
    Expert Opin Ther Pat; 2012 Feb; 22(2):95-105. PubMed ID: 22316395
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of p53 in cancer drug resistance and targeted chemotherapy.
    Hientz K; Mohr A; Bhakta-Guha D; Efferth T
    Oncotarget; 2017 Jan; 8(5):8921-8946. PubMed ID: 27888811
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The development of piperidinones as potent MDM2-P53 protein-protein interaction inhibitors for cancer therapy.
    Liao G; Yang D; Ma L; Li W; Hu L; Zeng L; Wu P; Duan L; Liu Z
    Eur J Med Chem; 2018 Nov; 159():1-9. PubMed ID: 30253242
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design of stapled peptide-based PROTACs for MDM2/MDMX atypical degradation and tumor suppression.
    Chen S; Li X; Li Y; Yuan X; Geng C; Gao S; Li J; Ma B; Wang Z; Lu W; Hu HG
    Theranostics; 2022; 12(15):6665-6681. PubMed ID: 36185610
    [No Abstract]   [Full Text] [Related]  

  • 33. Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapy: Progress and Challenges.
    Wang S; Zhao Y; Aguilar A; Bernard D; Yang CY
    Cold Spring Harb Perspect Med; 2017 May; 7(5):. PubMed ID: 28270530
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [NEGATIVE REGULATORS OF TUMOR SUPPRESSOR P53 IN THE CONTEXT OF ANTICANCER THERAPY].
    Shuvalov OY; Fedorova OA; Petukhov AV; Daks AA; Vasilieva EA; Grigorieva TA; Ivanov GS; Barlev NA
    Tsitologiia; 2015; 57(12):847-54. PubMed ID: 26995961
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface.
    Chène P
    Mol Cancer Res; 2004 Jan; 2(1):20-8. PubMed ID: 14757842
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of selective small molecule MDM2 degraders based on nutlin.
    Wang B; Wu S; Liu J; Yang K; Xie H; Tang W
    Eur J Med Chem; 2019 Aug; 176():476-491. PubMed ID: 31128449
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of new inhibitors of Mdm2-p53 interaction via pharmacophore and structure-based virtual screening.
    Atatreh N; Ghattas MA; Bardaweel SK; Rawashdeh SA; Sorkhy MA
    Drug Des Devel Ther; 2018; 12():3741-3752. PubMed ID: 30464405
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting the MDM2-p53 interaction for cancer therapy.
    Shangary S; Wang S
    Clin Cancer Res; 2008 Sep; 14(17):5318-24. PubMed ID: 18765522
    [TBL] [Abstract][Full Text] [Related]  

  • 39. When the guardian sleeps: Reactivation of the p53 pathway in cancer.
    Merkel O; Taylor N; Prutsch N; Staber PB; Moriggl R; Turner SD; Kenner L
    Mutat Res Rev Mutat Res; 2017 Jul; 773():1-13. PubMed ID: 28927521
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification and characterization of the first small molecule inhibitor of MDMX.
    Reed D; Shen Y; Shelat AA; Arnold LA; Ferreira AM; Zhu F; Mills N; Smithson DC; Regni CA; Bashford D; Cicero SA; Schulman BA; Jochemsen AG; Guy RK; Dyer MA
    J Biol Chem; 2010 Apr; 285(14):10786-96. PubMed ID: 20080970
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.